bionics industry

I'm Still Bullish on Ekso Bionics Stock – Here's Why

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - August 21, 2015

Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.

But the business case for EKSO's growth is very strong.

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - April 2, 2015

We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.

And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.